| タイトル |
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
|
| 著者 |
Sato Shuichi
Miyake Tatsuya
|
| 収録物名 |
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
|
| 巻 | 87 |
| 開始ページ | 13 |
| 終了ページ | 19 |
| 収録物識別子 |
ISSN 0011-393X
EISSN 1879-0313
|
| 主題 | |
| 言語 |
英語
|
| 資源タイプ | 学術雑誌論文 |
| 出版者 |
ELSEVIER SCIENCE INC
|
| 発行日 | 2017 |
| アクセス権 | メタデータのみ |
| 関連情報 |
[DOI] 10.1016/j.curtheres.2017.07.002
[PMID] 28912902
|
| 備考 | Dapagliflozin was developed by AstraZeneca, who provided funding for publication fees and development of the manuscript, but did not play any other role in the study design; collection, analysis, and interpretation of data; writing of the manuscript; or the decision to submit the manuscript for publication. HT and YK have received honoraria from AstraZeneca K.K. Funding to pay for editorial support and the Open Access publication charges for this article were provided by AstraZeneca K.K. and Ono Pharmaceutical Co, Ltd. The authors have indicated that they have no other conflicts of interest regarding the content of this article. |
